808 results on '"Zagouri, F"'
Search Results
2. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
3. Paraneoplastic pemphigus associated with squamous cell carcinoma of the cervix
4. Detection of hotspot PIK3CA mutations in primary tumors and plasma-cfDNA of breast cancer patients using a novel highly sensitive CE-IVD KIT
5. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
6. Immune checkpoint inhibitor administration during pregnancy: a case series
7. How we treat endocrine complications of immune checkpoint inhibitors
8. The effect of anthracycline-based chemotherapy on endothelial function and arterial stiffness in breast cancer patients
9. Characteristics and treatment patterns of patients with advanced/metastatic renal-cell carcinoma treated with first line checkpoint inhibitors. A Real-world experience
10. Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
11. Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy
12. ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer
13. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting
14. Paving the way for changing perceptions in breast surgery: a systematic literature review focused on oncological and aesthetic outcomes of oncoplastic surgery for breast cancer
15. 192MO DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
16. 79P Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: An observational study with concurrent investigation of significance of TILs
17. Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial
18. Axitinib as a third or further line of treatment in renal cancer: a single institution experience
19. OVARIAN CANCER TREATMENT IN THE ELDERLY: EP905
20. NEOADJUVANT CHEMOTHERAPY FOR NEWLY DIAGNOSED OVARIAN CANCER: A SINGLE CENTER EXPERIENCE: EP881
21. 77P The impact of COVID-19 on gynecological cancer diagnoses in Greece
22. Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial
23. Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG)
24. Cell-free DNA concentration in patients with different molecular subtypes of breast cancer
25. VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis
26. A Phase 3 Study of Pembrolizumab (Pembro) + Concurrent Chemoradiotherapy (CCRT) for High-Risk Locally Advanced Cervical Cancer (LACC): Safety Findings
27. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)
28. 709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
29. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
30. 27P Association between CD8+ tumor infiltrating lymphocytes and the clinical outcome of patients with operable breast cancer treated with adjuvant dose-dense chemotherapy: A 10-year follow up report of a Hellenic Cooperative Oncology Group observational study
31. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
32. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: Cell type is the most useful prognostic factor
33. 'The emerging role of capivasertib in breast cancer'
34. Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience
35. Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
36. Adjuvant Treatment of Elderly Breast Cancer Patients: Offer the Best Chances of Cure
37. High-throughput Proteomic Profiling of Male Breast Cancer Tissue
38. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
39. Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review
40. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial
41. Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors
42. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience
43. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma
44. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel
45. 816TiP Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician’s choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
46. P154 - Characteristics and treatment patterns of patients with advanced/metastatic renal-cell carcinoma treated with first line checkpoint inhibitors. A Real-world experience
47. Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case–control study
48. Safety outcomes from monarchE: phase 3 study of abemaciclib combined with endocrine therapy (ET) for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer (EBC)
49. Trastuzumab administration during pregnancy: un update
50. How we treat endocrine complications of immune checkpoint inhibitors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.